Parabolic Drugs Ltd., a vertically integrated API manufacturer and exporter in India, announced the unaudited results for quarter ended September 30th, 2011.

Q2FY12 Performance
The Companys sales increased by 33.30% to Rs. 215.19 crore as compared to Rs. 161.43 crore in Q2 FY 11
Net profit at Rs. 14.38 crore as compared to Rs. 14.29 crore in Q2 FY 11
EBITDA increased by 43.35% to Rs. 42.58 crore as compared to Rs. 29.70 Crore in Q2 FY 11
The companys EBIDTA margin was up 154 basis points to 21.77%
The companys net profit margin stood at 7.35% in Q2 FY12

H1FY12 Performance
Sales increased by 39.49% to Rs. 420.66 crore during H1FY12 as compared to Rs. 301.58 crore in H1FY11
Net profit up 19.12% at Rs. 29.57 crore as compared to Rs. 24.82 crore in H1FY11
EBITDA increased by 52.20% to Rs. 84.38 crore in H1FY12
The companys EBIDTA margin was up 189 basis points to 22.10%
The companys net profit margin stood at 7.74% in H1FY12

During the first half of FY 12, the company received an official accreditation from Japans Ministry of health, labour and Welfare designating it as a Certified Foreign Drugs Manufacturer for Cephalosporin Oral supplies to Japan which is world’s second largest drugs market. The impact of inflationary pressures across the economy has resulted in frequent interest hike by RBI. This had an undesirable impact on the profitability for the Q2.The company also filed its first DMF in Japan. This is companys 38th Regulatory filing and first in Japanese market. In the capacity additions, the company successfully accomplished the capacity expansion of its Amorphous production at Derabassi with the commissioning of eighth plant. Amongst the other strategic areas, there have been significant developments in the formulations space and CRAMS operations. The company has also filed its seventeenth patent application to Indian Patents office for a molecule in the Anti-diabetic therapy. In line with the diversified and global growth approach, PDL has advanced its market presence in some new countries chiefly in APAC, Africa and Latin America.

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

Related Pharma